Julen Fernandez-Plana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julen Fernandez-Plana has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Antonieta Salud
Medical Oncology Service, Hospital Universitari Arnau de Vilanova, Lleida, Spain
1 shared publication - Carla Cases
Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona, Spain
1 shared publication - Carles Conill
Hospital Clínic de Barcelona
1 shared publication - Carlos Fernandez Martos
Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
1 shared publication - Carlos Fernandez-Martos
Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
1 shared publication - Constantino Fondevila
Hepatopancreatobiliary Surgery & Transplantation, General & Digestive Surgery Service Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 14 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2131
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments.
- 14 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2131
Open AccessLimited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments.